Profound Medical Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Profound Medical hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	1.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-CA$1.14
Erwartete Dividendenrendite in 3 Jahren	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Here's Why We're Not Too Worried About Profound Medical's (TSE:PRN) Cash Burn Situation

Jan 07

We Think Profound Medical (TSE:PRN) Can Easily Afford To Drive Business Growth

Jul 02

We Take A Look At Why Profound Medical Corp.'s (TSE:PRN) CEO Compensation Is Well Earned

May 13

Analysts Expect Breakeven For Profound Medical Corp. (TSE:PRN) Before Long

May 07

We Think Profound Medical (TSE:PRN) Can Afford To Drive Business Growth

Mar 25

How Many Profound Medical Corp. (TSE:PRN) Shares Do Institutions Own?

Mar 04

Profound Medical Corp. (TSE:PRN) Is Expected To Breakeven In The Near Future

Jan 27

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von PRN in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von PRN gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Profound Medical Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von PRN im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (PRN)	n/a
Untere 25 % des Marktes (CA)	1.8%
Markt Top 25 % (CA)	6.6%
Branchendurchschnitt (Medical Equipment)	1.8%
Analystenprognose in 3 Jahren (PRN)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von PRN im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von PRN im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von PRN, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da PRN keine Ausschüttungen gemeldet hat.

Profound Medical Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Profound Medical Receives U.S. FDA 510(K) Clearance for Contour Assistant AI Module That Enables Creation of an Automated Tulsa Treatment Plan

New minor risk - Profitability

Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024

Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024

First quarter 2024 earnings released: US$0.26 loss per share (vs US$0.32 loss in 1Q 2023)

Forecast to breakeven in 2026

Does Profound Medical (TSE:PRN) Have A Healthy Balance Sheet?

Profound Medical Corp. to Report Q1, 2024 Results on May 09, 2024

Chief Commercial Officer of US recently sold CA$95k worth of stock

Chief Commercial Officer of US notifies of intention to sell stock

Profound Medical Corp., Annual General Meeting, May 15, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

Profound Medical Corp. to Report Q4, 2023 Results on Mar 07, 2024

Profound Medical Corp. announced that it expects to receive $2.937503 million in funding

Profound Medical Corp. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

Profound Medical Corp. has completed a Follow-on Equity Offering in the amount of $20.000003 million.

Profound Medical Corp. Announces CMD Extension of Temporary Code for TULSA to ASC Setting

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Profound Medical Corp. to Report Q3, 2023 Results on Nov 02, 2023

Profound Medical Corp. Receives U.S. FDA 510(k) Clearance for TULSA-PRO Thermal Boost

Is Profound Medical (TSE:PRN) Using Debt In A Risky Way?

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Profound Medical Corp. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Shareholder dilution

Profound Medical Announces New CPT® Category 1 Codes from the AMA for TULSA to Treat Prostate Diseases

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS and revenues miss analyst expectations

Profound Medical Corp. to Report Q4, 2022 Results on Mar 07, 2023

Chairman & CEO recently bought CA$138k worth of stock

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Profound Medical Corp. to Report Q3, 2022 Results on Nov 03, 2022

Profound Medical Corp. Announces Updated Results from the TACT (TULSA-PRO® Ablation Clinical Trial)

Profound Medical Corp. Announces Changes to Commercial Organization to Support Continued Growth

Will Profound Medical (TSE:PRN) Spend Its Cash Wisely?

Profound Medical Corp. Provides TULSA-PRO Reimbursement Update

Second quarter 2022 earnings released: US$0.28 loss per share (vs US$0.35 loss in 2Q 2021)

Profound Medical Corp. to Report Q2, 2022 Results on Aug 04, 2022

Independent Director recently bought CA$123k worth of stock

Profound Medical Corp. Elects Kris Shah to Board of Director

Profound Medical Corp. Unveils TULSA-PRO Software Release 2.11, Which Includes Two New Features

Independent Lead Director recently bought CA$459k worth of stock

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Profound Medical Corp. to Report Q1, 2022 Results on May 09, 2022

Chairman & CEO recently bought CA$637k worth of stock

Forecast to breakeven in 2024

No longer forecast to breakeven

Profound Medical Corp. Confirms the TULSA-PRO Systems New Compatibility with GE Healthcares 3T

Profound Medical Corp. to Report Q4, 2021 Results on Mar 03, 2022

Profound Medical Announces First Patients Treated in Prospective, Randomized Clinical Trial Comparing the Tulsa Procedure to Radical Prostatectomy

Here's Why We're Not Too Worried About Profound Medical's (TSE:PRN) Cash Burn Situation

Forecast to breakeven in 2024

Chairman & CEO recently bought CA$125k worth of stock

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.33 loss in 3Q 2020)

Chairman & CEO exercised options to buy CA$634k worth of stock.

Independent Director recently bought CA$127k worth of stock

Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.33 loss in 2Q 2020)

No longer forecast to breakeven

Consensus forecasts updated

We Think Profound Medical (TSE:PRN) Can Easily Afford To Drive Business Growth

Price target decreased to CA$29.55

Independent Director has left the company

Independent Lead Director recently bought CA$387k worth of stock

Forecast breakeven pushed back to 2024

Consensus revenue estimates fall to US$12.6m

First quarter 2021 earnings released

We Take A Look At Why Profound Medical Corp.'s (TSE:PRN) CEO Compensation Is Well Earned

Analysts Expect Breakeven For Profound Medical Corp. (TSE:PRN) Before Long

We Think Profound Medical (TSE:PRN) Can Afford To Drive Business Growth

Profound Medical Corp., Annual General Meeting, May 19, 2021

Full year 2020 earnings released: US$1.25 loss per share (vs US$1.37 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Profound Medical Announces the Appointment of Cynthia Lavoie to its Board of Directors